Colin Goddard, Ph.D., currently serves as executive chairman and chief executive officer of Coferon, chairman of Mission Therapeutics and is a director of biopharmaceutical companies Endocyte (NASDAQ: ECYT), Azelon Pharmaceuticals and PanOptica. Previously, he served as CEO of OSI Pharmaceuticals, Inc., from 1998 until its $4 billion acquisition by Astellas in 2010.

Dr. Goddard is actively involved in organizations that promote the advancement of cancer therapeutics and the biotechnology industry. He has served on the Boards of the New York Biotechnology Association (Chairman 2000-2002), Cancer Care of Long Island and is a member of the American Association of Cancer Research.

Dr. Goddard received a B.S. in biochemistry from the University of York, in York, United Kingdom and a Ph.D. in cancer pharmacology from Aston University in Birmingham, United Kingdom.